Bio-Gate Valuation

Q: What is the Fair Price of BIG1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BIG1 (€0.7) is trading below our estimate of [[fair value]] (€11.25)

Is BIG1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIG1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIG1 (€0.7) is trading below our estimate of fair value (€11.25)

Significantly Below Fair Value: BIG1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIG1?

Key metric: As BIG1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIG1. This is calculated by dividing BIG1's market cap by their current revenue.
What is BIG1's PS Ratio?
PS Ratio	0.9x
Sales	€7.61m
Market Cap	€6.47m

BIG1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	-3.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BIG1's PS Ratio compare to its peers?

The above table shows the PS ratio for BIG1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.6x
BNN BRAIN Biotech	1.1x	8.5%	€63.4m
2HRA H&R GmbH KGaA	0.1x	2.7%	€128.4m
NTG Nabaltec	0.6x	4.5%	€120.1m
UZU Uzin Utz	0.5x	4.3%	€243.1m
BIG1 Bio-Gate	0.9x	16.3%	€6.5m

Price-To-Sales vs Peers: BIG1 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does BIG1's PS Ratio compare vs other companies in the DE Chemicals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
2HRA H&R GmbH KGaA	0.1x	2.7%	US$135.19m
NSAK OTI Greentech	0.03x	n/a	US$604.76k
B7Y Byotrol	0.04x	n/a	US$246.97k

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BIG1 is good value based on its Price-To-Sales Ratio (0.9x) compared to the European Chemicals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is BIG1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIG1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.9x
Fair PS Ratio	0.6x

Price-To-Sales vs Fair Ratio: BIG1 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Tokuyama

JP¥189.7b

Produces and sells various chemical products in Japan.

TBT

JP¥15.90

-1.9%

12.0%

Central Asia Metals

UK£279.8m

Operates as a base metals producer.

9C3

UK£1.97

3.1%

2.1%

Cabka

€64.2m

Manufactures and sells pallets and large containers made from recycled plastic in Europe, North America, and internationally.

7GW

€2.54

-63.2%